University of Iowa Opioids Ideas Lab
- Discoverability
- Visible
- Join Policy
- Closed
- Created
- 27 Feb 2018
Substance Use
| A | B | C | D | E | |
|---|---|---|---|---|---|
|
1
|
OPPORTUNITY NUMBER | OPPORTUNITY TITLE | AGENCY NAME |
POSTED DATE
|
CLOSE DATE
|
|
2
|
RFA-DA-18-004 | Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2) | National Institutes of Health | 31/3/2017 | 13/11/2019 |
|
3
|
RFA-DA-18-023 | Identification of Biomarkers of HIV-1 Pathogenesis and Substance Abuse Comorbidity (R01- Clinical Trial Not Allowed) | National Institutes of Health | 21/12/2017 | 17/4/2018 |
|
4
|
PA-18-060 | Neuroscience Research on Drug Abuse (R01 Clinical Trial Optional) | National Institutes of Health | 3/11/2017 | 7/1/2020 |
|
5
|
PA-18-078 | Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional) | National Institutes of Health | 3/11/2017 | 7/1/2020 |
|
6
|
PA-17-119 | Basic Mechanisms of Brain Development Mediating Substance Use and Dependence (R01) | National Institutes of Health | 10/1/2017 | 7/1/2020 |
|
7
|
PA-18-057 | The Application of Big Data Analytics to Drug Abuse Research (R01 Clinical Trial Optional) | National Institutes of Health | 1/11/2017 | 7/5/2019 |
|
8
|
PAR-18-064 | Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) | National Institutes of Health | 8/11/2017 | 8/11/2018 |
|
9
|
PA-18-067 | Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional) | National Institutes of Health | 15/11/2017 | 7/5/2018 |
|
10
|
PA-18-073 | Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional) | National Institutes of Health | 2/11/2017 | 7/1/2019 |
|
11
|
SP-18-002 | Drug Free Communities - New |
Substance Abuse and Mental Health Services Adminis
|
12/1/2018 | 29/3/2018 |
|
12
|
PA-17-155 | Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R01) | National Institutes of Health | 8/2/2017 | 7/5/2020 |
|
13
|
PA-17-157 | Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R21) | National Institutes of Health | 8/2/2017 | 7/5/2020 |
|
14
|
PAR-17-250 | Extracellular Vesicles and Substance Use Disorders (R01) | National Institutes of Health | 4/4/2017 | 3/3/2020 |
|
15
|
PAR-17-242 | Extracellular Vesicles and Substance Use Disorders (R21) | National Institutes of Health | 4/4/2017 | 3/3/2020 |
|
16
|
PA-18-056 |
Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01 Clinical Trial Optional)
|
National Institutes of Health | 2/11/2017 | 7/9/2018 |
|
17
|
PA-18-075 |
Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21 Clinical Trial Optional)
|
National Institutes of Health | 2/11/2017 | 7/9/2018 |
|
18
|
PAR-18-086 | Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R21/R33 Clinical Trial Optional) | National Institutes of Health | 17/11/2017 | 7/9/2019 |
|
19
|
PAR-18-085 | Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R33 Clinical Trial Optional) | National Institutes of Health | 17/11/2017 | 7/9/2019 |
|
20
|
PAR-18-231 |
National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction (U19 Clinical Trial Optional)
|
National Institutes of Health | 21/11/2017 | 24/2/2020 |
|
21
|
PAR-18-218 | Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01 Clinical Trial Optional) | National Institutes of Health | 21/11/2017 | 25/7/2019 |
|
22
|
PAR-18-222 | Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional) | National Institutes of Health | 30/11/2017 | 13/11/2020 |
|
23
|
PAR-18-223 | Multi-Site Pilot and Feasibility Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34 Clinical Trial Optional) | National Institutes of Health | 30/11/2017 | 13/11/2020 |
|
24
|
RFA-DA-18-020 | NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3, Clinical Trial Optional) | National Institutes of Health | 6/12/2017 | 7/9/2020 |
|
25
|
PAR-18-494 | Device-Based Treatments for Substance Use Disorders (UG3/UH3) (Clinical Trial Optional) | National Institutes of Health | 15/12/2017 | 24/7/2020 |
|
26
|
PAR-18-226 | Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) | National Institutes of Health | 30/11/2017 | 19/10/2018 |
|
27
|
PA-18-074 | Behavioral and Integrative Treatment Development Program (R03 Clinical Trial Optional) | National Institutes of Health | 2/11/2017 | 7/1/2019 |
|
28
|
PA-18-076 | Prescription Drug Abuse (R21 Clinical Trial Optional) | National Institutes of Health | 2/11/2017 | 7/5/2019 |
|
29
|
PA-18-058 | Prescription Drug Abuse (R01 Clinical Trial Optional) | National Institutes of Health | 2/11/2017 | 7/5/2019 |
|
30
|
PA-16-145 | Role of Astrocytes and Astrocytic Networks in Drug Abuse (R21) | National Institutes of Health | 22/3/2016 | 7/5/2019 |
|
31
|
PA-16-144 | Role of Astrocytes and Astrocytic Networks in Drug Abuse (R01) | National Institutes of Health | 22/3/2016 | 7/5/2019 |
|
32
|
PA-18-066 | International Research Collaboration on Drug Abuse and Addiction Research (R21 Clinical Trial Optional) | National Institutes of Health | 15/11/2017 | 7/5/2018 |
|
33
|
PA-18-065 | International Research Collaboration on Drug Abuse and Addiction Research (R03 Clinical Trial Optional) | National Institutes of Health | 15/11/2017 | 7/5/2018 |
|
34
|
PAR-18-084 | Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional) | National Institutes of Health | 17/11/2017 | 7/9/2019 |
|
35
|
PA-18-568 | International Research Collaboration on Drug Abuse and Addiction Research (R01, Clinical Trial Optional) | National Institutes of Health | 9/1/2018 | 7/5/2018 |
|
36
|
PAR-18-062 | Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional) | National Institutes of Health | 1/11/2017 | 7/5/2019 |
|
37
|
PAS-18-063 | HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional) | National Institutes of Health | 1/11/2017 | 7/9/2018 |
|
38
|
PA-18-068 | Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34 Clinical Trial Optional) | National Institutes of Health | 15/11/2017 | 7/5/2018 |
|
39
|
PA-18-069 | Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R03 Clinical Trial Optional) | National Institutes of Health | 15/11/2017 | 7/5/2018 |
|
40
|
PA-18-070 | Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R21 Clinical Trial Optional) | National Institutes of Health | 15/11/2017 | 7/5/2018 |
|
41
|
PA-18-569 | Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01, Clinical Trial Optional) | National Institutes of Health | 17/1/2018 | 7/5/2018 |
|
42
|
PA-17-120 | Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01) | National Institutes of Health | 10/1/2017 | 7/1/2020 |
|
43
|
PAR-18-083 | NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Optional) | National Institutes of Health | 17/11/2017 | 7/9/2018 |
|
44
|
PA-18-055 | Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional) | National Institutes of Health | 2/11/2017 | 7/1/2019 |
|
45
|
PAR-18-224 | NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional) | National Institutes of Health | 30/11/2017 | 7/1/2019 |
|
46
|
PA-17-135 | Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R01) | National Institutes of Health | 25/1/2017 | 7/5/2020 |
|
47
|
PA-17-132 | Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R21) | National Institutes of Health | 25/1/2017 | 7/5/2020 |
|
48
|
PA-17-134 | Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R03) | National Institutes of Health | 25/1/2017 | 7/5/2020 |
|
49
|
PAR-17-153 | Advancing our Understanding of the Brain Epitranscriptomics (R01) | National Institutes of Health | 3/2/2017 | 7/5/2020 |
|
50
|
PAR-17-152 | Advancing Our Understanding of the Brain Epitranscriptome (R21) | National Institutes of Health | 3/2/2017 | 7/5/2020 |
|
51
|
PAR-17-313 | Global Brain and Nervous System Disorders Research Across the Lifespan (R21) | National Institutes of Health | 13/6/2017 | 7/11/2019 |
|
52
|
PAR-17-314 | Global Brain and Nervous System Disorders Research Across the Lifespan (R01) | National Institutes of Health | 13/6/2017 | 7/11/2019 |
|
53
|
PA-18-061 | Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R01 Clinical Trial Optional) | National Institutes of Health | 3/11/2017 | 7/5/2020 |
|
54
|
PA-18-079 | Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R21 Clinical Trial Optional) | National Institutes of Health | 3/11/2017 | 7/5/2020 |
|
55
|
PA-18-080 | Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R03 Clinical Trial Optional) | National Institutes of Health | 3/11/2017 | 7/5/2020 |
|
56
|
PAR-18-230 | National Cooperative Drug/Device Discovery/Development Groups (U01 Clinical Trial Optional) | National Institutes of Health | 21/11/2017 | 24/2/2020 |
|
57
|
PAR-18-082 | Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional) | National Institutes of Health | 17/11/2017 | 7/1/2019 |
|
58
|
PAR-18-225 | NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) | National Institutes of Health | 30/11/2017 | 7/1/2020 |
|
59
|
RFA-DA-18-019 | NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional) | National Institutes of Health | 6/12/2017 | 14/8/2020 |
|
60
|
HRSA-18-039 | Rural Health Clinic Policy and Clinical Assessment Program | Health Resources and Services Administration | 10/1/2018 | 16/3/2018 |
|
61
|
W81XWH18SBAA1 | DoD USAMRMC FY18-FY22 Broad Agency Announcement for Extramural Medical Research | Dept. of the Army -- USAMRAA | 1/10/2017 | 30/9/2022 |
|
62
|
RFA-674-12-000006 | Service Delivery and Support for Families Caring For Orphans and Vulnerable Children (OVC) | South Africa USAID-Pretoria | 7/5/2012 | |
|
63
|
RFA-CE-18-004 | Research to Evaluate Medication Management of Opioids and Benzodiazepines to Reduce Older Adult Falls |
Centers for Disease Control and Prevention - ERA
|
21/12/2017 | 23/3/2018 |
|
64
|
CDC-RFA-OT18-1804 | Technical Assistance for Response to Public Health or Healthcare Crises | Centers for Disease Control - OSTLTS | 16/1/2018 | 16/3/2018 |